Many tyrosine kinase inhibitors (TKIs) have been developed to suppress the tumor‐promoting properties caused by EGFR mutations in non‐small‐cell lung cancer (NSCLC) patients [4, 5]. This evidence concerns the gene EGFR and neoplasm.